Pierre Saintigny is a medical oncologist and physician-scientist at Centre Léon Bérard in Lyon, heavily involved in the development of translational research programs. He is affiliated to the Department of Medical Oncology, to Alain Puisieux’ team (EMT and Cancer Cell Plasticity) at Cancer Research Center of Lyon and to the Department of Translational Research and Innovation where he is the Director of the Laboratory of Translational Research and coordinates the Unit of Tumor Characterization. He is focusing his research on the lung and head and neck field. He is actively involved in the large scale sequencing program AURAGEN in the context of Plan France Médecine Génomique 2025.
Éric Postaire is a pharmacist and Docteur es Sciences. He is a member of the French National Academy of Pharmacy and Chevalier of the Order of Academic Palms. As a hospital pharmacist at the Paris Hospitals (1980) / Associate Professor at the University of Paris Sud (1992), he has developed research in clinical pharmacy in the direction of clinical methodology for therapeutic research on drugs and specific medical approaches such as: hemodialysis, medical devices, enteral and parenteral nutrition. At the same time, he set up a basic research, the results of which allowed establishing relationships between oxidative stress and immune functions. He was in 1994 at the origin of the creation of a company specialized in analytical chemistry: Ar2i, which became Neovix Biosciences with a current capital of more than 5M€.
In 2003, he joined Inserm to set up the clinical research department at the institute’s headquarters, where he was able to develop the national network of clinical investigation centers and Biological Resource Centers (Biobanks), Inserm’s clinical research promoter activities in connection with the strategic orientation and monitoring committee for clinical trials, biotherapies in Inserm units, etc. In 2007, he participated in the implementation of the thematic networks of research and care (RTRS) from the General Directorate for Research and Innovation of the Ministry of Higher Education and Research.
Since 2010, he is advisor to the Secrétaires perpétuels of the French Academy of Sciences.
Pr. Erik Goormaghtigh is a european leader in the field of FTIR spectroscopy of biological molecules, cells and tissues with 252 publications in peered reviewed journals, 10,901 citations and a H factor =54, numerous invited conferences at international congresses or summer schools and participations to thesis juries abroad. About 20 years ago, E. Goormaghtigh started studying cancer cells grown in culture or 3D media, then tissue sections obtain from tumor resection in collaboration with different hospital in Belgium, France and Switzerland. This generated millions of FTIR spectra. He designed and built the tools and analyses necessary to exploit this wealth of information.Most publications and patents report FTIR spectroscopy advances.
In the academic, he occupied the position of Research Director with the National Fund for Scientific Research (Belgium), Professor at the Faculty of Sciences at the Université Libre de Bruxelles (ULB), President of a doctoral school, President of the Chemistry Department (ULB), co-director of the Center for Structural Biology and Bioinformatics (ULB).
Henri Porte is Vice-President of the Photonics activity of the iXblue group. With a scientific background, he obtained a PhD in optics and signal processing from the University of Besançon in 1985. He then joined the CNRS (French National Center for Scientific Research) as a researcher at the PM Duffieux Optics Laboratory. He developed a research activity in the field of optical modulators based on lithium niobate. In 1998, as CNRS Research Director, he participated in the creation of the Franco-American Laboratory “GTL-CNRS-Telecom” in Metz, in partnership with Georgia Tech of Atlanta University. In 2000, he founded Photline Technologies in Besançon and became its CEO. In 2014, Photline joined the iXblue group. Today, he is the Deputy Managing Director. Henri Porte has published more than 150 articles in scientific journals and international conferences, he is co-inventor of eighteen patents, and has directed a dozen thesis.
Pharmacist, PhD in analytical chemistry and former Paris Hospital’s Intern. After a first industrial experience as Chief of Quality Control Laboratory at Johnson & Johnson (Val de Reuil, France), Christian Sarbach founded in 1994 AR2i, CRO involved in R&D in Analytical Chemistry, Quality Control of pharmaceutical products, and Regulatory Affairs consulting. He is now CEO and Qualified Person of AR2i. CS is also President of Neovix Biosciences group, involved in the support of pharmaceutical and cosmetic laboratories for Development, Regulatory, Quality and Compliance of Computerized Systems.